September 2009 IMPORTANT DRUG INFORMATION Dear Healthcare Professional: Roche would like to advise you that production of ZENAPAX® (daclizumab) Sterile Concentrate for Injection has been discontinued for the United Stat

First Page		Document Content
Daclizumab Transplantation medicine Monoclonal antibody therapy Transplant rejection Medicine Immunosuppressants Immunology		September 2009 IMPORTANT DRUG INFORMATION Dear Healthcare Professional: Roche would like to advise you that production of ZENAPAX® (daclizumab) Sterile Concentrate for Injection has been discontinued for the United Stat Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 54,77 KB Share Document on Facebook

	Medication Guide ZINBRYTA™ (zin-bry-tuh) (daclizumab) injection, for subcutaneous use What is the most important information I should know about ZINBRYTA? ZINBRYTA can cause serious side effects, including: DocID: 1t3jF - View Document
	Prescribing Information - ZINBRYTA™ (daclizumab) DocID: 1sY6a - View Document
	TABLE OF CONTENTS INTRODUCTION 2 DocID: 1pRFl - View Document
	p&s cover/SPR[removed]:56 AM Page C4 COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS & SURGEONS 630 WEST 168TH STREET NEW YORK, NY 10032 DocID: C2NP - View Document
	FREILICHER & ASSOCIATES, COURT REPORTERS[removed]Village Square Terrace, Suite 101 Rockville, Maryland[removed]8132 DocID: rJ1w - View Document